Find clinical trials

This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of?sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of?sotatercept?and if people tolerate it over a longer period of time.

The purpose of this Expanded Access Program (EAP) is to provide continued access to LP352, an Investigational Medicinal Product (IMP), which has no marketing authorisations anywhere in the world and which is being investigated in patients with Developmental and Epileptic Encephalopathies (DEEs). Within Australia, the EAP will; allow participants of LP352-201 and LP352-202 (approved by CHQ HREC, QCH lead site) to continue to access this treatment after the participant has successfully completed the LP352-202 trial (rollover patient), or provide treatment for an immediate family member of a participant that completed the LP352-202 trial who has the exact same gene mutation resulting in the same DEE phenotype (nave participant).

This is a global Phase 3 double-blind, randomized, Placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with developmental epileptic encephalopathies (DEEs). Randomisation will be stratified by 4 categories of age (2 to 5 years, 6 to 11 years, 12 to 17 years, and 18 to 65 years) and 2 categories of country region categories (Asian, not Asian). The study consists of the following periods for all participants: Screening (approximately 5 weeks), Titration (3 weeks or Days 1 to 21), and Maintenance (12 weeks or Days 22 to 105). Participants not entering the open-label extension (OLE) will complete Taper (up to 2 weeks) and Follow-up (4 weeks after completing Taper).

This is a global Phase 3 double-blind, randomized, Placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with Dravet syndrome. Randomisation will be stratified by 4 categories of age (2 to 5 years, 6 to 11 years, 12 to 17 years, and 18 to 65 years) and 2 categories of country region categories (Asian, not Asian). The study consists of the following periods for all participants: Screening (approximately 5 weeks), Titration (3 weeks or Days 1 to 21), and Maintenance (12 weeks or Days 22 to 105). Participants not entering the open-label extension (OLE) will complete Taper (up to 2 weeks) and Follow-up (4 weeks after completing Taper).

The trial is testing a novel model of care employing standardised titration of low dose combinations of blood pressure (BP) and cholesterol lowering agents compared to usual care in survivors of ischaemic stroke/transient ischaemic attack (TIA). The design is open-label and will require three in-person study visits for both arms – at enrolment, week 12 and at week 26, to capture data on clinic BP, lipid levels, medication prescriptions, adherence to medication, visit frequency and adverse events. A 26-week intervention will enable assessment of the short and medium-term effects of the intervention on risk factor control, tolerability and translatability into practice.

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 [COAST-1], EFC17560 [COAST 2], EFC17561 [SHORE]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal.